Innovation + Divide...
Health Care: Drugs
Neurocrine Biosciences Inc. (NBIX: NASDAQ)
$9.37 -0.09 | -0.95%
02/08/12 - 04:00 PM ET
338.86K / 364.90K
Vol / Avg. Vol:9.46 / 9.46
Open / Prev. Close:9.21 - 9.51
Today's Range:5.42 - 9.98
52 Wk Range:10.24%
Performance YTD:TheStreet Rating:
Portfolios with NBIX
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Drug Stock Winners of 2010
- UserKareem Portfolio
- UserSUPRATRADE Top 10 Micro Cap...
- UserBVF Inc.
- UserRAPTOR SPRTD-1110080822
- UserDblD01
- Userburrex Portfolio 1
- Userlwillett Portfolio 1
Latest NBIX Headlines from TheStreet
- Neurocrine Biosciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript 02.08.12 | 08:02 pm
- Neurocrine Stock Hits New 52-Week High (NBIX) 01.30.12 | 11:01 am
- Neurocrine Stock Falls On Unusually High Volume (NBIX) 01.19.12 | 10:01 am
- Neurocrine Stock Hits New 52-Week High (NBIX) 12.29.11 | 10:12 am
- Neurocrine Biosciences Presentation At 2011 Credit Suisse Annual Health Care Conference - Conference Call Transcript 11.09.11 | 05:11 pm
- Neurocrine Biosciences' CEO Discusses Q3 2011 Results - Earnings Call Transcript 10.31.11 | 11:10 pm
- Neurocrine Biosciences Inc. Stock Downgraded (NBIX) 08.04.11 | 07:08 am
- Neurocrine Biosciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.29.11 | 01:07 pm
- Neurocrine Biosciences Inc. Stock Upgraded (NBIX) 06.06.11 | 08:06 am
- Neurocrine Rises On Unusually High Volume (NBIX) 05.31.11 | 04:05 pm
Press Releases for NBIX
- Neurocrine Biosciences To Present At The 14th Annual BIO CEO & Investor Conference - PR Newswire 02.06.12 | 04:02 pm
- Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2011 Financial Results - PR Newswire 02.02.12 | 03:02 pm
- Neurocrine Biosciences, Inc. Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares - PR Newswire 01.30.12 | 04:01 pm
- Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854 - PR Newswire 01.25.12 | 08:01 am
- Neurocrine Mourns The Passing Of Founder And Board Member Wylie Vale, Ph.D. - PR Newswire 01.07.12 | 12:01 am
- Neurocrine Biosciences To Present At The 30th Annual J.P. Morgan Healthcare Conference - PR Newswire 01.06.12 | 08:01 am
- Neurocrine Biosciences To Present At The 23rd Annual Piper Jaffray Health Care Conference - PR Newswire 11.23.11 | 01:11 pm
- Neurocrine Biosciences To Present At The 2011 Credit Suisse Annual Health Care Conference - PR Newswire 11.03.11 | 02:11 pm
- Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2011 Financial Results - PR Newswire 10.26.11 | 03:10 pm
- Neurocrine Biosciences Receives Second Milestone Payment Of $20 Million Under Abbott Collaboration Agreement - PR Newswire 10.04.11 | 04:10 pm
Partner Headlines for NBIX
- 10 Small-Cap Stocks With Strong Profitability And Plenty Of Cash On Hand - Seeking Alpha 11.04.11 | 08:11 am
- Neurocrine Biosciences (NBIX) - Bull of the Day - Zacks 11.02.11 | 01:11 am
- 10 Overvalued Healthcare Stocks - Seeking Alpha 10.25.11 | 08:10 am
- Insider Buying And A Pending Catalyst Send Neurocrine Bioscience's Shares Higher - Seeking Alpha 10.17.11 | 07:10 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Piper Jaffray Maintains Overweight on Neurocrine Biosciences (NBIX) - Benzinga 03.25.11 | 09:03 am
- Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share - Benzinga 12.22.10 | 09:12 am
- Bullish on Neurocrine Bio After Latest Clinical Trials - Seeking Alpha 12.08.10 | 08:12 am
- Best Performing Stocks Year to Date - Seeking Alpha 11.01.10 | 09:11 am
- Neurocrine Biosciences (NBIX) - Bull of the Day - Zacks 11.01.10 | 01:11 am
